Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Issued (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Shares Issued data on record, last reported at -$5.1 million in Q2 2025.

  • For Q2 2025, Shares Issued fell 2920.56% year-over-year to -$5.1 million; the TTM value through Sep 2025 reached $12.7 million, up 677.69%, while the annual FY2024 figure was $14.2 million, 728.01% up from the prior year.
  • Shares Issued reached -$5.1 million in Q2 2025 per NWBO's latest filing, down from $5.1 million in the prior quarter.
  • Across five years, Shares Issued topped out at $12.7 million in Q4 2024 and bottomed at -$5.1 million in Q2 2025.
  • Average Shares Issued over 5 years is $2.6 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Shares Issued: soared 10572.27% in 2024, then plummeted 2920.56% in 2025.
  • A 5-year view of Shares Issued shows it stood at $7.9 million in 2021, then plummeted by 85.78% to $1.1 million in 2022, then tumbled by 89.37% to $119000.0 in 2023, then skyrocketed by 10572.27% to $12.7 million in 2024, then crashed by 139.98% to -$5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$5.1 million in Q2 2025, $5.1 million in Q1 2025, and $12.7 million in Q4 2024.